Next Article in Journal
From Fertilisation to Implantation in Mammalian Pregnancy—Modulation of Early Human Reproduction by the Endocannabinoid System
Next Article in Special Issue
Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Previous Article in Journal
Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
Previous Article in Special Issue
Cobalt Complexes as Antiviral and Antibacterial Agents
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species

by
Marie Stéphanie Goka Chekem
1,
Paul Keilah Lunga
1,
Jean De Dieu Tamokou
1,
Jules Roger Kuiate
1,*,
Pierre Tane
3,
Gerard Vilarem
2 and
Muriel Cerny
2
1
Laboratory of Microbiology and Antimicrobial Substances, Faculty of Science, University of Dschang, P.O. Box 67 Dschang, Cameroon
2
ENSIACET, Laboratoire de Chimie Agro-Industrielle, 4, Allée Emile Monso, 31432 Toulouse Cedex 4, France
3
Laboratory of Natural Products, Faculty of Science, University of Dschang, P.O. Box 67 Dschang, Cameroon
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(9), 2900-2909; https://doi.org/10.3390/ph3092900
Submission received: 15 May 2010 / Revised: 6 July 2010 / Accepted: 14 July 2010 / Published: 1 September 2010
(This article belongs to the Special Issue Anti-Infective Agents)

Abstract

:
The essential oil of the aerial part (leaves, flowers and stem) of Chenopodium ambrosioides was obtained by hydrodistillation and its chemical composition analyzed by GC and GC/MS, which permitted the identification of 14 components, representing 98.8% of the total oil. Major components were α-terpinene (51.3%), p-cymene (23.4%) and p-mentha-1,8-diène (15.3%). The antifungal properties of this essential oil were investigated in vitro by the well diffusion and broth microdilution methods. The in vitro antifungal activity was concentration dependent and minimum inhibitory concentration values varied from 0.25 to 2 mg/mL. The in vivo antifungal activity was evaluated on an induced vaginal candidiasis rat model. The in vivo activity of the oil on mice vaginal candidiasis was not dose-dependent. Indeed, all the three tested doses; 0.1%, 1% and 10% led to the recovery of mice from the induced infection after 12 days of treatment. The effect of the essential oil on C. albicans ATCC 1663 fatty acid profile was studied. This oil has a relatively important dose-dependent effect on the fatty acids profile.

Graphical Abstract

1. Introduction

Candidiasis is an opportunistic infection caused by fungal species of the genus Candida, predominantly Candida albicans. Candida species are ubiquitous fungi that represent the most common fungal pathogens that affect humans. The growing problem of mucosal and systemic candidiasis reflects the enormous increase in the number of patients at risk and the increased opportunity that exists for Candida species to invade tissues normally resistant to invasion [1]. Several factors contribute to this situation, including immunodeficiency in HIV-infected persons that results in patients who are more susceptible to fungal infections. About 77% of immune-deficient patients’ deaths are caused by fungi, including Candida species [2,3]. About 75% of women must have had at least one episode of vulvo-vaginal candidiasis, which is considered the second most common form of vaginitis after bacterial vaginosis. during their lives [4]. It is also important to mention that drug-resistant Candida strains have been reported [5,6].
Commonly used drugs that eradicate fungal infections are the imidazoles and polyenes [7,8]. Polyene antifungal agents such as amphotericin B interact with membrane sterols resulting in production of an aqueous pore that leads to altered cellular permeability [9]. On the other hand, fatty acids are potent targets for some antifungal compounds since they form part of the major building blocks of fungal cells [9]. In addition to the fact that some of these drugs have relatively high toxic effects and are relatively expensive, their antifungal spectra are usually limited to a reduced number of fungal species [10].
In the recent years, there has been growing interest in antifungal essential oils from natural products, and interesting results have been obtained for azole-susceptible and -resistant Candida species with the essential oil of Melaleuca alternifolia (tea tree) [11]. The essential oil of Chenopodium ambrosioides is known to inhibit the growth of dermatophytes [12] and other filamentous fungi such as Aspergillus, Fusarium and Colletotrichum [13]. It equally possesses anti-aflatoxigenic, antimalarial and antioxidant properties [14] as well as antihelmintic and worm expelling activities [15]. To the best of our knowledge, the antifungal properties of this oil against yeast species are being reported here for the first time, with emphasis on the fatty acid profiles. The present work was thus designed to evaluate the in vitro and in vivo antifungal properties of C. ambrosioides essential oil on some human pathogenic yeast species and equally its effects on fatty acid profiles of Candida albicans in order to contribute to a possible standardization of this oil in the treatment of vaginal candidiasis.

2. Results and Discussion

2.1. Chemical composition of the essential oil

The hydrodistillation of the aerial part of C. ambrosioides gave a yellowish essential oil (0.12%). Fourteen components, all monoterpenes, were identified, with α- terpinene (51.3%), p-cymene (23.4%) and p-mentha-1,8-diene (15.3%) being the most abundant (Table 1).
Table 1. Chemical composition (%) of the essential oil of the aerial part of C. ambrosioides.
Table 1. Chemical composition (%) of the essential oil of the aerial part of C. ambrosioides.
ConstituentsRI%
1α-Pinene9360.1
2α-Terpinene102851,3
3p-Cymene103523,4
4Limonene10360,9
5β-Phellandrene10380,2
6γ-Terpinene10630,7
7Dehydro-p-cymene10960,1
8L-Carvacrol11280,1
9p-Mentha-1,8-diene129115,3
10Oxyde de piperitone13020,4
11Ascaridole13050,7
12Thymol13320,2
13Carvacrol13400,3
14Isoascaridole13475,1
All constituents were identified by Gas Chromatography-Flame Ionization Detector and Gas Chromatography-Mass Spectrometry; RI: Retention Index.
These results were significantly different from those obtained by Tapondjou et al. [16] for an oil sample extracted from dry leaves of C. ambrosioides collected from the same geographical area. It is possible that during the drying process some of the chemical constituents underwent chemical transformations and disappeared. This may be the case with p-mentha-1,8-diene and some other constituents that were absent in the sample of Tapondjou et al. [16]. These differences can also be due to physiological variation, genetic factors and the evolution as well as the harvest time and period [17]. Also, from the results published so far, the concentration of the main constituents of C. ambrosioides oil varies considerably. The concentration of ascaridole, described as a quality indicator of this oil [15] was very low in Cameroonian, Nigerian [18] and Indian [19] samples. In contrast, ascaridoles appear to be the main constituents of the Brazilian [13], Togolese [20] and French commercial essential oil samples [21]. Although the chemical composition of the oil can be influenced by environmental factors, these disparities in results may also suggest the existence of chemotypes in C. ambrosioides plant species.

2.2. Antifungal properties

All the tested microorganisms were sensitive to the essential oil in the in vitro antifungal study and this activity was concentration-dependent (Table 2). MIC values varied from 0.25 to 2 mg/mL with C. glabrata and C. guilliermondi (MIC = 0.25 mg/mL) being the most sensitive while C. albicans ATCC 2091(MIC = 2 mg/mL) was the most resistant. C. glabrata presented the smallest MFC (0.25 mg/mL). However, this in vitro antifungal activity was lower than that of nystatin used as reference antifungal agent.
Table 2. Minimum Inhibitory Concentrations (MIC) and Minimum Fungicidal Concentrations (MFC) of essential oil of C. ambrosioides on Candida strains.
Table 2. Minimum Inhibitory Concentrations (MIC) and Minimum Fungicidal Concentrations (MFC) of essential oil of C. ambrosioides on Candida strains.
MicroorganismMICMFC
Essential oil (mg/mL)Nystatin (µg/mL)Essential oil (mg/mL)Nystatin (µg/mL)
C. albicans ATCC 90021.001.002.002.00
C. albicans ATCC 20912.001.002.002.00
C. albicans ATCC 16631.001.002.004.00
C. glabrata0.251.000.251.00
C. guilliermondi0.251.000.252.00
C. krusei1.001.002.004.00
C. lusitaneae1.002.001.004.00
C. parapsilosis0.500.501.001.00
C. tropicalis1.000.501.001.00
Tabulated values are the means of three trials which did not show any variation.
Many other biological activities of the essential oil of C. ambrosioides have been reported. It possesses antifungal activities on dermatophytes [12] and other filamentous fungi such as Aspergillus, Fusarium and Colletotrichum [13]. This is however the first time the antifungal properties of this oil are being investigated in vitro and in vivo on Candida species with emphasis on its effect on fungal fatty acid profiles. This antifungal activity varied with the fungal species and for the same species with the strain. These variations may be due to genetic differences between the microorganisms.
The effect of the essential oil on fatty acid profile reveals that the global fatty acid quantity decreased with increasing oil concentration. The relative concentration of each fatty acid in the microorganisms was also dependent on the oil concentration used, with some fatty acids being more affected than others, while some even disappeared (Figure 1). Fungi subjected to a concentration of 0.0625 mg/mL synthesized pentadecanoate and pentadecenoate, but as the oil concentration increased these fatty acids were no longer present in the fungal extract. These results suggest that the microorganism fights against the oil by using these fatty acids to re-enforce the membrane impermeability, but the higher oil concentration seems to inhibit the enzymes involved in their synthesis.
Figure 1. Effect of the essential oil of C. ambrosioides on the relative proportion of fatty acids in C. albicans fatty acid profiles.
Figure 1. Effect of the essential oil of C. ambrosioides on the relative proportion of fatty acids in C. albicans fatty acid profiles.
Pharmaceuticals 03 02900 g001
Fatty acids are major building blocks of cell membranes [22]. In this study, we found that the ratio of unsaturated-to-saturated fatty acids decreases from 1.6 to 0.2, associated with a shift from C18 (oleate and linoleate) to C16 (palmitate) (Figure 1). Similar results have been reported with naftifine and tolnaftate which are inhibitors of ergosterol synthesis [9]. Thus, it is probable that the essential oil of C. ambrosioides elicites a response against Candida by impairing ergosterol synthesis. This suggests that the oil may affect membrane fluidity and permeability and consequently protein function, increasing possibly the uptake of undesired substances by fungal cells. It is the case with chitosan on sensitive fungi for which more polyunsaturated fatty acids are produced compared to non-sensitive, suggesting that their permeabilization by chitosan may be dependent on membrane fluidity [11,22]. This perturbation of membrane integrity and architecture may distort membrane function [23,24] and may explain the antifungal activity of the essential oil. Membrane saturation may play an important role in the effectiveness of antifungals [25].
The therapeutic effect of the oil on mice vaginal candidiasis model showed that the infection was established in all experimental animals two days after inoculation with C. albicans. The treatment of these animals with oil solutions at doses of 0.1%, 1% and 10% (weight/volume) induced an important time-decrease in the number of yeast colonies in vaginal fluid of infected animals (Figure 2). This antifungal effect was not dose-dependent in vivo. All the animals that received the three essential oil doses got healed within 12 days of treatment as those treated with nystatin (0.01%). The healing effect of C. ambrosioides oil was more rapid compared to that reported by Mondello et al. [11] for the essential oil of Melaleuca alternifolia which at a dose of 1% (weight/volume) healed mice infected with C. albicans after 23 days of treatment. Also, tepinen-4-ol, the main bioactive component of this oil showed good activity in controlling C. albicans vaginal candidiasis.
Figure 2. Evolution of healing effect of the essential oil of C. ambrosioides on vaginal candidiasis model in rat as a function of oil concentration.
Figure 2. Evolution of healing effect of the essential oil of C. ambrosioides on vaginal candidiasis model in rat as a function of oil concentration.
Pharmaceuticals 03 02900 g002

3. Experimental

3.1. Plant material, oil extraction and chemical composition

The aerial part (leaves, flowers and stem) of C. ambrosioides was collected on the Dschang University Campus in August 2008 and its taxonomic identification performed at the National Herbarium of Yaounde/Cameroon. A voucher specimen was deposited in the Herbarium of the Biochemistry Department of the University of Dschang. The essential oil was obtained by hydrodistillation for 5 h of fractions of fresh aerial plant material (3000 g) using a Clevenger-type apparatus. The oil obtained was dried over a column of anhydrous sodium sulphate and stored in dark bottles at +4 ºC until analysis.
The chemical composition of the essential oil of C. ambrosioides was determined by GC and GC/MS. The GC analysis was carried out using a Hewlett-Packard model 5890 apparatus fitted with a DB-5 fused silica column (30 m × 0.32 mm, 0.25 µm film thickness). The oven temperature was programmed from 50 to 200 ºC at 5 ºC/min. The injector and detector (FID) temperatures were fixed at 200 ºC and 250 ºC respectively.
The GC-MS analysis were carried out using an Agilent 6890N Network GC system/5975 Inert x L Mass selective Detector at 70 eV and 20 ºC. The GC column was a CP- Sil 8 CB LB, fused silica capillary column (0.25 mm × 30 m, film thickness 0.25 µm). Helium was used as carrier gas at a flow rate of 1.6 mL/min. The injector port was maintained at 250 ºC; the oven temperature was programmed at 5 ºC/min from 50 ºC. The split ratio was 1:100. One microliter of pure essential oil was injected into the GC and GC-MS apparatus. The retention indices were calculated relative to C8-C19 n-alkanes. The constituents were identified by comparison of their retention indices with those of the literature (Pherobase-Kovats Indices) and by matching the mass spectra data with those stored in NIST05 and Wiley237 database libraries.

3.2. Antifungal assay

3.2.1. Fungi strains and culture media

The microorganisms used in this study were C. albicans ATCC 9002, C. albicans ATCC 2091, C. albicans ATCC 1663, C. parapsilosis ATCC 22019, C. tropicalis ATCC 750, C. krusei ATCC 6258, C. parapsilosis ATCC 22019 and C. lusitaniae ATCC 200950. The C. albicans ATCC 1663 strain was used for the in vivo studies and for the determination of the effect of the oil on fatty acids profile. C. albicans is the major Candida species causing oral and vaginal candidiasis and systemic infection which has frequently recurred in the immunocompromised patients [26].
Sabouraud Dextrose Agar (SDA) culture medium (Liofilchem Laboratories) was used for the determination of inhibition zone diameters and for sub-culturing during minimum fungicidal concentration determination. Sabouraud Dextrose Broth (Conda) was used for the determination of minimum inhibitory and fungicidal concentrations and for the study of the oil’s effect on fungal fatty acid profiles.

3.2.2. Determination of minimum inhibitory concentrations and minimum fungicidal concentrations

The in vitro antifungal properties of Chenopodium ambrosioides essential oil were measured using the microdilution method [27]. The inoculum suspensions were prepared from 24 h colonies grown on an agar plate of SDA and inoculated into saline physiological solution to yield a 0.5 McFarland turbidity standard suspension corresponding to about 1.5 × 108 CFU/mL. From these prepared suspensions, other dilutions with saline physiological solution were done to give a final concentration of 2 × 105 CFU/mL. Stock solution (160 mg/mL) of Chenopodium ambrosioides essential oil dissolved in Tween 80 (5%) was two-fold serially diluted to give 80–0.625 mg/mL concentration range.
Ninety six well sterile plates (IWAKI) were filled with Sabouraud Dextrose Broth (185 µL). Ten microliters of essential oil solutions were introduced in each well and 5 µL (2 × 105 CFU/mL) of yeast suspension were added. A growth well (broth and inoculum) and a sterility control well (broth only) were included in each panel. The plates were then incubated at 35 ºC for 48 h on a rotating shaker (Titertek) at 300 rpm. Minimum inhibitory concentration (MIC) was determined as the smallest oil concentration at which no increase in visual turbidity was observed [27]. Minimum fungicidal concentration (MFC) was determined by plating 10 µL from each negative well and from the positive growth control on SDA. MFC was defined as the lowest concentration yielding negative subcultures or only one colony [28]. All the experiments were carried out in triplicate. Nystatin served as reference antibiotic.

3.2.3. Effect of C. ambrosioides essential oil on C. albicans fatty acid profiles

3.2.3.1. Fungal culture and fatty acid extraction

C. albicans ATCC 1663 strain was used in this study. Five sets of three 100 mL conical flasks each were prepared and 50 mL of Sabouraud dextrose broth medium and essential oils at final crather Tween 20 at 1% concentration. Into each conical flask was introduced a 2 × 105 CFU/mL suspension of C. albicans (400 µL). These preparations were incubated under constant mechanical shaking (Titertek) at 35 ºC for 48 h. The biomass was harvested by centrifugation at 1,500 rpm for 15 min. The sludge (yeast cells) was washed with methanol and fungal fatty acids extracted as below. The method described by the protocols of the MIDI chromatographic system was used for fatty acids extraction [29]. The procedure began by a saponification step using NaOH 3.75 M-methanol 50% (1/1, v/v, 1 mL) and fungal biomass (1 mg) in test tubes. This mixture was vortexed for 5 to 10 seconds, and heated in a boiling water bath for 5 min. Tubes were vortexed again for 10 seconds and returned to the boiling water bath for 25 min. The tubes were then cooled to room temperature and the methylation process followed by the addition of a 6.0 M solution of HCl/methanol (13/11, v/v, 2 mL). The homogenized mixture was heated at 80 ºC for 10 min and rapidly cooled using tap water. The methylated fatty acids were then extracted by adding hexane/methyl tert-butyl ether (1/1, v/v, 1.25 mL) and gently mixed by continuous immersion for 10 min. The topmost phase containing the methylated fatty acids was collected and washed with 0.3 M NaOH (3 mL). Two-thirds (2/3) of the organic phase was transferred into chromatographic vial for GC analysis.

3.2.3.2. Fatty acid profile analysis

Hexane was removed from the samples by evaporation and then pure hexane (50 µL) was added to each vial. The analysis was carried out in triplicate in a Varian 3900 Gas Chromatograph equipped with a CP–Select CB for FAME fused silica WCOT column, 50 m long, 0.25 mm interior diameter, 0.25 µm film thickness. The oven temperature was programmed at 185 ºC for 40 min and 15 ºC/min up to 250 ºC and at 250 ºC for 10 min. Injection split was 1:100 and the sample volume injected was 1 µL. Detector and FID temperature were fixed at 250 ºC. The identification of individual FAME was done on the basis of their retention time relative to a mixture of standards FAME: capric acid, lauric acid, myristic acid, myristoleate, pentadecanoate, pentadecenoate, palmitate, palmitoleate, stearate, oleate, linolenate, arachidonic acid.

3.2.4. Evaluation of therapeutic effect of C. ambrosioides essential oil

Pathogen-free female albino Swiss mice (6 weeks old) were used for the candidiasis experiments. These animals were bred in the animal house of the Faculty of Science of the University of Dschang. Animal experiments were carried out according to the guidelines provided by the Ethic Committee of the University of Dschang.
Thirty five mice previously acclimatized for one week were distributed into seven groups of five animals each. Animals were injected subcutaneously with 0.1 mL of a solution of oestradiol (0.5mg/mL) [4]. Animals were infected intravaginally using 10 µL of C. albicans suspension (1.5 × 108 CFU/mL) [25]. The different groups were treated as follows:
  • Group 1 received nystatin at 0.01% (positive control),
  • Group 2 was infected and not treated (negative control),
  • Group 3 was infected and received 10 µL of Tween 80 solution 1%,
  • Group 4 was not infected and did not receive any substance,
  • Group 5, 6 and 7 were infected and treated with 0.1, 1 and 10% of essential oil solutions (test groups).
Administration of substances was done by intravaginal instillation of 10 µL of each substance on day 1, 2 and 3, then every two days up to day 15. The evolution of the infection was monitored by making vaginal cultures from each animal on SDA and the number of yeast colonies counted.

3.3. Statistical analysis

The one way analysis of variance (One Way ANOVA) was used to analyze the number of colonies and results were expressed as mean ± standard deviation. The results were compared using the Waller-Duncan test at a 5% probability level.

4. Conclusions

Based on these results, one of the possible modes of action of this oil is to effect lipid biosynthesis and particularly that of fatty acids. Fatty acids are among the major building blocks of living cells, making lipid biosynthesis a potent target for antifungal substances. The essential oil of C. ambrosioides may be used in the treatment of vaginal candidiasis in combination with other natural antifungal substances. But further studies in the evaluation of its toxicity as well as pharmacokinetic-pharmacodynamic parameters should be envisaged.

References

  1. Klepser, M.E. Antifungal resistance among Candida species. Pharmacotherapy 2001, 21, 124s–132s. [Google Scholar] [CrossRef] [PubMed]
  2. Mohammad, A.H.; Shigefumi, M.; Kotaro, M.; Hiroshi, K.; Eisuke, S.; Kazunori, T.; Takayoshi, T.; Shigera, K. In vitro and in vivo activities of SCH56592 against Cryptococcus neoformans. J. Antimicrob. Chemother. 1999, 44, 827–829. [Google Scholar] [CrossRef] [PubMed]
  3. Sean, O.H.; Renee, N.M. Candidiasis. Emerg. Med. 2006, 19, 1–11. [Google Scholar]
  4. Fidel, P.; Lynch, M.E.; Sobel, J.D. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect. Immunol. 1993, 61, 4201–4207. [Google Scholar]
  5. Goff, D.A.; Koletar, S.L.; Buesching, W.J.; Banishan, J.; Fass, R.J. Isolation of fluconazole-resitant Candida albicans from human immunodeficiency virus-negative patients never treated with azole. Clin. Infect. Dis. 1995, 20, 77–83. [Google Scholar] [CrossRef] [PubMed]
  6. Dupont, B.F.; Dromer, F.; Improvisi, L. The problem of resistance to azoles in Candida. J. Med. Mycol. 1996, 6, 12–19. [Google Scholar]
  7. Heeres, J.; Meerpoel, L.; Lewi, P. Conazoles. Molecules 2010, 15, 4129–4188. [Google Scholar]
  8. Ellepolla, A.N.B.; Samaranayake, L.P. Oral candidal infections and antimycotics. Rev. Oral Biol. Med. 2000, 11, 172–198. [Google Scholar]
  9. Georgopadakou, N.A.; Dix, B.A.; Smith, S.A.; Freudenberger, J. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob. Agents Chemother. 1987, 31, 46–51. [Google Scholar] [PubMed]
  10. Kauffman, C.A.; Carver, P.L. Antifungal agents in the 1990s. Current status and future developments. Drugs. 1997, 53, 539–549. [Google Scholar] [CrossRef] [PubMed]
  11. Mondello, F.; De Bernardis, F.; Girolamo, A.; Cassone, A.; Salvatore, G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and resistant human pathogenic Candida species. BMC Infect Dis. 2006, 6, 1–8. [Google Scholar] [CrossRef] [PubMed]
  12. Kishore, N.; Chansouria, J.P.N.; Dubey, N.K. Antidermatophytic action of the essential oil of Chenopodium ambrosioides and an ointment prepared from it. India Phytother. Res. 1999, 10, 453–455. [Google Scholar]
  13. Jardim, C.M.; Jham, G.N.; Dhingra, O.D.; Freire, M.M. Composition and antifungal activity of the essential oil of the Brazilian Chenopodium ambrosioides L. J. Chem. Ecol. 2008, 34, 1213–1218. [Google Scholar] [CrossRef] [PubMed]
  14. Kumar, R.; Kumar, M.A.; Dubey, N.K.; Tripathi, Y.B. Evaluation of Chenopodium ambroisioides oil as a potential source of antifungal, antiaflatoxigenic and antioxidant activity. Int. J. Food Microbiol. 2007, 115, 159–164. [Google Scholar] [CrossRef] [PubMed]
  15. Potawale, S.E.; Luniya, K.P.; Mantri, R.A.; Mehta, U.K.; Waseem, M.D.; Sadiq, M.D.; Vetal, Y.D.; Deshmukh, R.S. Chenopodium ambrosioides: An ethnopharmacological review. Pharmacologyonline 2008, 2, 272–286. [Google Scholar]
  16. Tapondjou, A.L.; Adler, C.; Bouda, H.; Fontem, A.D. Bioefficacy of powders and essential oil from leaves of C. ambrosoides and E. saligna to the cowpea bruchid Collosobruchus maculatus Fab. (coleoptera. Bruchidae). Cahiers d’études et de Recherches Francophones/Agricultures 2003, 12, 401–408. [Google Scholar]
  17. Figueiredo, A.C.; Barroso, J.G.; Pedro, L.G.; Scheffer, J.J.C. Factors affecting secondary metabolite production in plants: volatile components and essential oils. Flavor Frag. J. 2008, 23, 213–226. [Google Scholar] [CrossRef]
  18. Onocha, P.A.; Ekundayo, O.; Eramo, T.; Laakso, I. Essential oil constituents of Chenopodium ambrosioides L. leaves from Nigeria. J. Essent. Oil Res. 1999, 11, 220–222. [Google Scholar]
  19. Gupta, D.; Charles, R.; Mehta, V.K.; Garg, S.N.; Kumar, S. Chemical examination of the essential oil of Chenopodium ambrosioides L. from the southern hills of India. J. Essent. Oil Res. 2002, 14, 93–94. [Google Scholar]
  20. Koba, K.; Catherine, G.; Raynaud, C.; Chaumont, J.P.; Sanda, K.; Laurence, N. Chemical composition and cytotoxic activity of Chenopodium ambrosioides L. essential oil from Togo. Bangladesh J. Sci. Ind. Res. 2009, 44, 435–440. [Google Scholar]
  21. Cavalli, J.F.; Tomi, F.; Bermadini, A.F.; Casanova, J. Combined Analysis of the Essential oil of Chenopodium ambrosioides by GC, GC-MS and 13C NMR Spectroscopy: Quantitative Determination of Ascaridole, a Heat Sensitive Compound. Phytochem. Anal. 2004, 15, 275–279. [Google Scholar] [PubMed]
  22. Mondello, F.; De Bernardis, F.; Girolamo, A.; Salvatore, G.; Cassone, A. In vitro and in vivo activity of tea tree oil against azole-susceptible and resistant human pathogenic yeasts. J. Antimicrob. Chemother. 2003, 51, 1223–1229. [Google Scholar] [PubMed]
  23. Giorgione, J.; Epand, R.M.; Buda, C.; Farkas, T. Role of phospholipids containing docohexaenoyl chains in modulating the activity of protein kinase C. Proc. Natl. Acad. Sci. USA 1995, 92, 9767–9770. [Google Scholar]
  24. Ntambi, J.M.; Bene, H. Polyunsaturated fatty acid regulation of gene expression. J. Mol. Neurosci. 2001, 16, 273–278. [Google Scholar]
  25. Ells, R.; Kock, J.L.F.; Van Wyk, P.W.J.; Botes, P.J.; Pohl, C.H. Arachidonic acid increases antifungal susceptibility of Candida albicans and Candida dubliniensis. J. Antimicrob. Chemother. 2009, 63, 124–128. [Google Scholar] [PubMed]
  26. Shigeharu, I.; Miki, T.; Shigeru, A. Inhibitory activity of hydrosols, herbal teas and related essential oils against filament formation and growth of Candida albicans. Jpn. J. Med. Mycol. 2009, 50, 243–251. [Google Scholar] [CrossRef]
  27. National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts.; National Committee for Clinical Laboratory Standards: Wayne, PA, US, 2002; Approved Standard M27-A2.
  28. Tamokou, J.D.; Tala, F.M.; Wabo, H.K.; Kuiate, J.R.; Tane, P. Antimicrobial activities of methanol extract and compounds from stem bark of Vismia rubescens. J. Ethnopharmacol. 2009, 124, 571–575. [Google Scholar] [CrossRef] [PubMed]
  29. Da Silva, M.; Manfio, G.P.; Canhos, V.P. Characterization of selected strain of Mucorales using fatty acid profiles. Rev. Microbiol. 1998, 29, 1–8. [Google Scholar]

Share and Cite

MDPI and ACS Style

Chekem, M.S.G.; Lunga, P.K.; Tamokou, J.D.D.; Kuiate, J.R.; Tane, P.; Vilarem, G.; Cerny, M. Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species. Pharmaceuticals 2010, 3, 2900-2909. https://doi.org/10.3390/ph3092900

AMA Style

Chekem MSG, Lunga PK, Tamokou JDD, Kuiate JR, Tane P, Vilarem G, Cerny M. Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species. Pharmaceuticals. 2010; 3(9):2900-2909. https://doi.org/10.3390/ph3092900

Chicago/Turabian Style

Chekem, Marie Stéphanie Goka, Paul Keilah Lunga, Jean De Dieu Tamokou, Jules Roger Kuiate, Pierre Tane, Gerard Vilarem, and Muriel Cerny. 2010. "Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species" Pharmaceuticals 3, no. 9: 2900-2909. https://doi.org/10.3390/ph3092900

Article Metrics

Back to TopTop